EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Rapid luminescence-based screening method for SARS- CoV-2 inhibitors discovery

Abdeldjalil Madani, Nadine Alvarez, Steven Park, Madhuvika Murugan, David S Perlin

SLAS Discovery · 2025

DOI: 10.1016/j.slasd.2025.100211 ↗

Kurz gefasst

Fachartikel in der Zeitschrift SLAS Discovery, 2025. Verfasst von Abdeldjalil Madani und 4 weiteren Autor:innen. Beteiligte Einrichtung: Center for Discovery and Innovation, Hackensack Meridian Health, 111 Ideation Way. Nutley, New Jersey 07110, United States. Electronic address: Abdel…. Hauptthemen laut MEDLINE: Antiviral Agents, SARS-CoV-2, Drug Discovery, COVID-19 Drug Treatment. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases Division of Microbiology and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The COVID-19 pandemic has emphasized the necessity for rapid and adaptable drug screening platforms against live pathogenic viruses that require high levels of biosafety containment. Conventional antiviral testing is time-consuming and labor-intensive. Here, we outline the design and validation of a semi-automated drug-screening platform for SARS-CoV-2 that utilizes multiple liquid handlers, a stable A549 cell line expressing ACE2 and TMPRSS2 receptors, and a recombinant SARS-CoV-2 strain harboring the nano-luciferase gene. This platform allows for accelerated low-, mid-, and high-throughput screenings by bypassing the virus inactivation and the staining steps compared to assays utilizing fluorescent reporter viruses or immunofluorescence. First, we demonstrated that the luminescence signal obtained at 24 h post-infection is robust and can be used as a surrogate for fluorescent reporter viruses and immunofluorescence assays that require 48 h incubation post infection. We confirmed the susceptibility of the reporter virus to a panel of reference drugs and validated the luminescence signal in 96- and 384-well plates in accordance with NIH criteria for high-throughput screening. The validation assays showed reproducible results, robust Z factor of ≥0.5, and a coefficient of variation of

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsSARS-CoV-2Drug DiscoveryCOVID-19 Drug TreatmentHumansHigh-Throughput Screening AssaysA549 CellsDrug Evaluation, PreclinicalCOVID-19Luminescent MeasurementsLuminescenceAngiotensin-Converting Enzyme 2

Stichwörter der Autor:innen

AntiviralsBsl-3 virusesDrug screeningHTSMMV global health priority boxNano-luciferaseSARS-CoV-2Viruses

Substanzen

Antiviral AgentsAngiotensin-Converting Enzyme 2

Autor:innen und Institutionen

  • Center for Discovery and Innovation, Hackensack Meridian Health, 111 Ideation Way. Nutley, New Jersey 07110, United States. Electronic address: Abdeldjalil.Madani@hmh-cdi.org.
  • Center for Discovery and Innovation, Hackensack Meridian Health, 111 Ideation Way. Nutley, New Jersey 07110, United States.
  • Center for Discovery and Innovation, Hackensack Meridian Health, 111 Ideation Way. Nutley, New Jersey 07110, United States. Electronic address: David.perlin@hmh-cdi.org.

Förderung

  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases Division of Microbiology and Infectious Diseases

Zitieren

APA

Madani, A., Alvarez, N., Park, S., Murugan, M., & Perlin, D. S. (2025). Rapid luminescence-based screening method for SARS- CoV-2 inhibitors discovery. SLAS Discovery. https://doi.org/10.1016/j.slasd.2025.100211

Vancouver

Madani A, Alvarez N, Park S, Murugan M, Perlin DS. Rapid luminescence-based screening method for SARS- CoV-2 inhibitors discovery. SLAS Discovery. 2025. doi:10.1016/j.slasd.2025.100211

BibTeX
@article{Madani2025,
  author = {Madani, Abdeldjalil and Alvarez, Nadine and Park, Steven and Murugan, Madhuvika and Perlin, David S},
  title = {Rapid luminescence-based screening method for SARS- CoV-2 inhibitors discovery},
  journal = {SLAS Discovery},
  year = {2025},
  doi = {10.1016/j.slasd.2025.100211}
}
Kostenlos starten →